Nonalcoholic Steatohepatitis: Call to Action
This activity has been archived and credit is no longer available.
In this presentation, Dr. Fasiha Kanwal. M.D., MSHS, discusses the epidemiology of the umbrella diagnosis of "non-alcoholic steatohepatitis," as well as patient screening and risk stratification, and guidelines for disease management. She emphasizes the necessity of standardizing processes for screening and treatment for these patients.
This Department of Medicine Grand Rounds session took place on Thursday, December 9, 2021 at 12:15 P.M. and was approved for MOC Credit.
Activity Information
This activity has been archived and credit is no longer available.
Needs Statement
Faculty and trainees within the Department of Medicine who are involved in the care of patients need to be regularly updated with the recent advances and guidelines in the fields of internal medicine and quality improvement to increase clinical knowledge, and to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.
Educational Objectives
At the conclusion of this activity, the participant should be able to:
- Recognize the recent shift in the epidemiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
- Demonstrate greater understanding of the rationale behind screening for NAFLD/NASH in terms of what, who, and how to screen.
- Review evidence-based management strategies for patients with NAFLD/NASH.
Target Audience
Professional Categories
- Physicians
- Medical Students
- Fellows
- Residents
Specialties
- Internal Medicine
Interest Groups
- Hospital Medicine
Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Activity Director
Term of Approval
December 1, 2021 through December 31, 2023. Original release date: December 1, 2021.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Presenter
-
Fasiha Kanwal, M.D., MSHS
Professor and Section Chief of Gastroenterology and Hepatology
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Activity Director
-
Richard J. Hamill, M.D.
Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Moderna TX, Inc. (Chair, Adjudication Committee)
Planning Committee Members
-
Richard J. Hamill, M.D.
Professor
Baylor College of Medicine
Disclosure:
- Advisory Committee Membership: Moderna TX, Inc. (Chair, Adjudication Committee)
-
Erica Lescinskas, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Ruchit Rana, M.D.
Internal Medicine Resident
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Zaven Sargsayan, M.D.
Assistant Professor
Baylor College of Medicine and Ben Taub Hospital
Disclosure:
Nothing to disclose.
-
Chirayu Shah, M.D., M.Ed.
Associate Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
-
Stephanie Sherman, M.D.
Assistant Professor
Baylor College of Medicine
Disclosure:
Nothing to disclose.
Health Topics
Presenter: